Pim2 is important for regulating DNA damage response in multiple myeloma cells

por Ramachandran, J, Santo, L, Siu, K T, Panaroni, C, Raje, N
Publicado 2016

Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma

por Wang, Y, Yee, A J, Sirard, C, Landau, S, Raje, N, Mahmood, U
Publicado 2017

MicroRNA expression patterns in medullary and extramedullary plasmacytoma

por Lin, J J, Mahindra, A, Santo, L, Amin, S, Sohani, A R, Raje, N
Publicado 2014

Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.

por Raje, N., Powles, R., Horton, C., Millar, B., Shepherd, V., Middleton, G., Kulkarni, S., Eisen, T., Mehta, J., Singhal, S., Treleaven, J.
Publicado 1997

P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAP...

por Voorhees, P., Suman, V., Efebera, Y., Raje, N., Tuchman, S., Rodriguez, C., Santo, K., Bova-Solem, M., Carlisle, D., Saad, U., McCarthy, P., Richardson, P.
Publicado 2022

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

por Raje, N, Vadhan-Raj, S, Willenbacher, W, Terpos, E, Hungria, V, Spencer, A, Alexeeva, Y, Facon, T, Stewart, A K, Feng, A, Braun, A, Balakumaran, A, Roodman, G D
Publicado 2016

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

por Dalovisio, A., Bahlis, N., Raje, N., Costello, C., Dholaria, B., Solh, M., Levy, M., Tomasson, M., Dube, H., Damore, M., Jiang, S., Basu, C., Skoura, A., Chan, E., Trudel, S., Jakubowiak, A., Chu, M., Gasparetto, C., Sebag, M., Lesokhin, A.
Publicado 2022

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T...

por Facon, T., Kumar, S. K., Plesner, T., Moreau, P., Bahlis, N., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Borgsten, F., Usmani, S. Z.
Publicado 2022

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

por Richardson, P G, Hofmeister, C C, Raje, N S, Siegel, D S, Lonial, S, Laubach, J, Efebera, Y A, Vesole, D H, Nooka, A K, Rosenblatt, J, Doss, D, Zaki, M H, Bensmaine, A, Herring, J, Li, Y, Watkins, L, Chen, M S, Anderson, K C
Publicado 2017

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

por Richardson, P. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S., Lonial, S., Laubach, J., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J., Doss, D., Zaki, M. H., Bensmaine, A., Herring, J., Li, Y., Watkins, L., Chen, M. S., Anderson, K. C.
Publicado 2018

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

por Weisel, K., Kumar, S., Moreau, P., Bahlis, N., Facon, T., Plesner, T., Orlowski, R., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C., Raje, N., Tiab1, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Krevvata, M, Carson, R, Borgsten, F., Usmani, S.
Publicado 2023